LakeShore Biopharma Co., Ltd (LSB)
CN — Healthcare Sector
Peers:
Automate Your Wheel Strategy on LSB
With Tiblio's Option Bot, you can configure your own wheel strategy including LSB - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol LSB
- Rev/Share 20.4846
- Book/Share 39.4031
- PB 0.1965
- Debt/Equity 0.7253
- CurrentRatio 1.1258
- ROIC -0.2372
- MktCap 147704625.4464
- FreeCF/Share 0.0
- PFCF 0.0
- PE -0.4395
- Debt/Assets 0.2805
- DivYield 0
- ROE -0.4936
- Rating
- Score
- Recommendation
- P/E Score
- DCF Score
- P/B Score
- D/E Score
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| No ratings available. | |||||||
News
LakeShore Biopharma Announces the Official Launch of a Novel Packaging Solution for YSJA™ Rabies Vaccine (Vero Cell)
LSB
Published: April 23, 2025 by: PRNewsWire
Sentiment: Neutral
Published: April 23, 2025 by: PRNewsWire
Sentiment: Neutral
Revolutionizing Vaccination Safety with Needle-Free Reconstitution Technology BEIJING , April 23, 2025 /PRNewswire/ -- On April 18, 2025, LakeShore Biopharma Co., Ltd. (Nasdaq: LSB) ("LakeShore Biopharma" or the "Company") successfully held the 2025 CSO ("Contract Sales Organization") Annual Meeting and the launch meeting of YSJA™ rabies vaccine (Vero cell) novel packaging solution (liquid drug transfer device) in Changsha, Hunan Province.
Read More
About LakeShore Biopharma Co., Ltd (LSB)
- IPO Date 2021-08-05
- Website https://www.ysbiopharm.com
- Industry Biotechnology
- CEO Wang Xu
- Employees 758
LakeShore Biopharma Co., Ltd, a biopharmaceutical company, engages in discovering, developing, manufacturing, and commercializing of vaccines and therapeutic biologics for infectious diseases and cancer. The company develops a proprietary PIKA immunomodulating technology platform and a series of product targeting PIKA rabies vaccine, PIKA recombinant COVID-19 vaccine, and PIKA YS-ON-001. It operates in China, the United States, Singapore, the United Arab Emirates, and the Philippines. The company was formerly known as YS Biopharma Co., Ltd. and changed its name to LakeShore Biopharma Co., Ltd in May 2024. LakeShore Biopharma Co., Ltd was founded in 2002 and is based in Beijing, China.